POSB51 A Cost-Effectivess Analysis of Trastuzumab Emtansine Versus Trastuzumab for the Adjuvant Treatment of Patients with Residual Invasive HER2-Positive Breast Cancer in Portugal
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.324
https://www.valueinhealthjournal.com/article/S1098-3015(21)02119-7/fulltext
Title :
POSB51 A Cost-Effectivess Analysis of Trastuzumab Emtansine Versus Trastuzumab for the Adjuvant Treatment of Patients with Residual Invasive HER2-Positive Breast Cancer in Portugal
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02119-7&doi=10.1016/j.jval.2021.11.324
First page :
Section Title :
Open access? :
No
Section Order :
11096